PubMed Health⌕ Search

Biomedical subjects

W H Robertson

Publications and source records attributed to W H Robertson.

14 recordsLinked to original sources
PubMed1997

Effect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty.

OBJECTIVE: To investigate the effect of low dose oxandrolone and testosterone on the pituitary-testicular and GH-IGF-I axes. DESIGN: Prospective double-blind placebo-controlled trial. PATIENTS: Sixteen boys with constitutional delay of growth and puberty (CDGP) with testicular volumes 4-6 ml were randomized to 3 months treatment: Group 1 (n = 5), daily placebo: Group 2 (n = 5), 2.5 mg oxandrolone daily or Group 3 (n = 6), 50 mg testosterone monthly intramuscular injections with assessment (growth, pubertal development and overnight hormone profiles) at 0, 3, 6 and 12 months. MAIN OUTCOME MEASURES: LH and GH profiles (15-minute samples) were analysed by peak detection (Pulsar), Fourier transformation and autocorrelation. Testosterone levels were measured hourly and insulin, SHBG, IGF-I, and IGFBP-3 levels at 0800 h. Statistical analysis was by multivariate analysis of variance for repeated measures. RESULTS: LH and testosterone parameters increased significantly with time in all 16 (LH AUC, P < 0.001; peak amplitude, P = 0.02; number of peaks, P = 0.02; testosterone AUC, P = 0.02; morning testosterone, P = 0.002). In Group 2, however, LH and testosterone parameters decreased at 3 months followed by a rebound increase at 6 and 12 months. SHBG levels were markedly reduced at 3 months (P = 0.006) and a wider range of dominant GH frequencies was present although GH AUC was not increased until 6 months, with an increase in GH pulse frequency but not amplitude. IGF-I levels were increased at both 3 and 12 months. In Group 3, pituitary-testicular suppression was not apparent, but GH levels increased with an increase in GH amplitude at 3 and 12 months. CONCLUSION: Oxandrolone transiently suppressed the pituitary-testicular axis and altered GH pulsatility. Testosterone increased GH via amplitude modulation.

Adolescent↗
PubMed1988

Mycology of vulvovaginitis.

The life cycle of the yeast Candida is characterized by rapid budding, maturation, and degeneration. Pathogenic species and strain differences are identified and these differences are important in the study of recurrent infections. The relationships between Candida and other fungi, and between Candida and hormones, are discussed.

Adrenal Cortex Hormones↗
PubMed1985

The problem of patient compliance.

The problem of noncompliance is an increasing and vexing one. Major reasons for this dilemma include a growing skepticism concerning the ability and dedication of the health care industry, as well as a growing population of older people. A review of medical history reveals ancient attitudes toward compliance. There are special problems for special people, such as infants, children, adolescents, elderly persons, and those who are hostile or have a "sick" wish or "death" wish. Persons who require long-term therapy require special care. Child abuse and abuse of elderly persons may be involved. Problems of decreased visual acuity, color perception, and deafness must be dealt with on an individual basis. The responsibility of the physician, which includes nonobtrusive monitoring, is stressed. Consideration is given to the pharmaceutical industry and the role it can play to help mitigate the problem. In conclusion, anticipation of the problem and improved doctor-patient relationships will achieve desired results.

Attitude↗
PubMed1982

Patient compliance and the short-term treatment regimen.

Patient compliance is necessary for the delivery of adequate health care. It is a major problem that must be addressed by the medical profession. Good communication between the physician and the patient is essential. Those known to be poor compliers should be identified and special techniques used to overcome particular obstacles. Methods designed to improve patient cooperation are discussed. Emphasis is placed upon the short-term therapeutic regimen and its role in improving compliance.

Candidiasis, Vulvovaginal↗
PubMed1980

A concentrated therapeutic regimen for vulvovaginal candidiasis.

Two therapeutic regimens were used to treat vulvovaginal candidiasis with clotrimazole vaginal tablets. The purpose of this study was to compare the efficiency of a three-day double-dose schedule with that of a seven-day single-dose schedule. Both regimens were comparable in eliminating the Candida sp.

Aged↗
PubMed1978

Vulvovaginal candidiasis treated with clotrimazole cream in seven days compared with fourteen-day treatment with miconazole cream.

Clotrimazole 1 per cent vaginal cream administered daily over a seven-day period was compared with miconazole nitrate 2 per cent vaginal cream administered daily over a 14 day period for the treatment of vulvovaginal candidiasis in a double-blind study of 65 women with clinical symptoms of this condition,, for whom treatment was randomly allocated. When efficacy of treatment was evaluated in 44 of these patients, a success rate, based on both clinical and mycologic criteria, of 75 per cent was found in the 20 patients treated with clotrimazole for seven days as compared with a 63 per cent success rate in the 24 patients treated with miconazole for 14 days. Of the 65 women enrolled in the study, two of the miconazole-treated patients experienced burning sensations, whereas the clotrimazole-treated patients experienced no adverse reactions. Thus, in this group of patients clotrimazole 1 per cent vaginal cream was shown to have a slightly, but not significantly, better efficacy than the miconazole nitrate 2 per cent vaginal cream, with no adverse reactions and in half the treatment time.

Adolescent↗
PubMed1976

Genital candidiasis: topical management with clotrimazole.

Clotrimazole was administered in the form of 100 mg tablets to patients with vaginal candidiasis, and in the form of a 1% solution to patients with cutaneous candidiasis of the genital and perigenital areas. The clinical and mycological response observed and the excellent tolerance and lack of side effects indicate that clotrimazole may be proposed as a treatment for candidiasis.

Administration, Oral↗
PubMed1975

Medical clerisy.

Explore the source record for details and available documents.

Language↗